European Commission Approves Bristol-Myers Squibb’s ORENCIA (abatacept) for the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis Not Previously Treated with Methotrexate
- Source Link:
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
ORENCIA is the first biologic therapy with an EU indication specifically applicable to the treatment of MTX-naive RA patients with highly active and progressive diseaseThis approval marks the first time that MRI assessment of structural and inflammatory measures of disease severity are cited in SmPC to support an RA indication
Slingshot Insights Explained
Don’t see a project related to the catalyst you care about?